• In recent published literature, a low Body Mass Index (BMI) condition, defined as a value <18.5, is mostly evaluated in low/middle-income settings while in Western Countries it was frequently evaluated in the pre- or early antiretroviral treatment (ART) era. • Nevertheless, in recent years BMI and weight gain returned to be investigational issues especially for the observed excessive weight increase under integrase strand-transfer inhibitors (INSTI) treatment, especially with dolutegravir (DTG) and raltegravir (RAL) use. • A BMI <18.5 cumulatively affects about 5% of HIV-infected population and might be related not only to complex clinical conditions but also to socio-economic issues. • A BMI <18.5 is associated with an increased risk of death for both cardiovascular and neoplastic disease (with an OR 2.47 for males and 1.60 for females). • An excessive weight gain in the first year of treatment has a strong impact on the development of cardiovascular disease and diabetes. • However, a low BMI at baseline could have different meaning and diverse consequences compared to a persisting low BMI after ART start; additionally, few data are available on BMI normalization (expression of general conditions improvement) in terms of virologic and immunologic recovery, especially with the availability of modern ART drugs.

Low Body Mas Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort.

G. Nunnari;G. F. Pellicanò.
2019-01-01

Abstract

• In recent published literature, a low Body Mass Index (BMI) condition, defined as a value <18.5, is mostly evaluated in low/middle-income settings while in Western Countries it was frequently evaluated in the pre- or early antiretroviral treatment (ART) era. • Nevertheless, in recent years BMI and weight gain returned to be investigational issues especially for the observed excessive weight increase under integrase strand-transfer inhibitors (INSTI) treatment, especially with dolutegravir (DTG) and raltegravir (RAL) use. • A BMI <18.5 cumulatively affects about 5% of HIV-infected population and might be related not only to complex clinical conditions but also to socio-economic issues. • A BMI <18.5 is associated with an increased risk of death for both cardiovascular and neoplastic disease (with an OR 2.47 for males and 1.60 for females). • An excessive weight gain in the first year of treatment has a strong impact on the development of cardiovascular disease and diabetes. • However, a low BMI at baseline could have different meaning and diverse consequences compared to a persisting low BMI after ART start; additionally, few data are available on BMI normalization (expression of general conditions improvement) in terms of virologic and immunologic recovery, especially with the availability of modern ART drugs.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3147224
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact